Federated Hermes Inc. cut its stake in Amgen, Inc. (NASDAQ:AMGN) by 10.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,016,059 shares of the medical research company’s stock after selling 124,054 shares during the quarter. Amgen comprises about 0.6% of Federated Hermes Inc.’s investment portfolio, making the stock its 29th biggest position. Federated Hermes Inc.’s holdings in Amgen were worth $205,986,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently added to or reduced their stakes in AMGN. Salomon & Ludwin LLC grew its stake in shares of Amgen by 125.0% during the fourth quarter. Salomon & Ludwin LLC now owns 108 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 60 shares in the last quarter. CLS Investments LLC grew its stake in shares of Amgen by 175.4% during the fourth quarter. CLS Investments LLC now owns 157 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 100 shares in the last quarter. Altshuler Shaham Ltd grew its stake in shares of Amgen by 273.9% during the fourth quarter. Altshuler Shaham Ltd now owns 172 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 126 shares in the last quarter. Column Capital Advisors LLC grew its stake in shares of Amgen by 98.0% during the first quarter. Column Capital Advisors LLC now owns 194 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 96 shares in the last quarter. Finally, Moser Wealth Advisors LLC acquired a new stake in shares of Amgen during the fourth quarter valued at about $48,000. 75.75% of the stock is currently owned by institutional investors.

NASDAQ:AMGN traded down $2.82 during midday trading on Wednesday, hitting $220.90. 2,477,953 shares of the stock were exchanged, compared to its average volume of 2,647,870. Amgen, Inc. has a one year low of $170.56 and a one year high of $244.99. The company has a market capitalization of $133.48 billion, a price-to-earnings ratio of 17.17, a P/E/G ratio of 1.93 and a beta of 0.94. The business has a 50-day moving average price of $231.88 and a two-hundred day moving average price of $225.59. The company has a current ratio of 1.59, a quick ratio of 1.28 and a debt-to-equity ratio of 3.16.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $4.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.70 by $0.47. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $6.01 billion. During the same quarter in the previous year, the company earned $3.56 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. Sell-side analysts forecast that Amgen, Inc. will post 15.58 EPS for the current fiscal year.

Several analysts have recently weighed in on AMGN shares. Barclays started coverage on Amgen in a research note on Thursday, February 27th. They set an “equal weight” rating and a $235.00 target price for the company. Piper Sandler lifted their price target on Amgen from $235.00 to $255.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Raymond James upgraded Amgen from a “market perform” rating to an “outperform” rating and set a $255.00 price target for the company in a research note on Sunday, March 29th. Oppenheimer assumed coverage on Amgen in a research note on Friday, May 1st. They issued a “buy” rating and a $252.00 price target for the company. Finally, Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $240.00 price target for the company in a research note on Wednesday, April 15th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seventeen have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $244.81.

In other Amgen news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total value of $100,856.75. Following the transaction, the director now owns 5,834 shares in the company, valued at $1,384,466.54. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ronald D. Sugar sold 1,000 shares of Amgen stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $233.35, for a total transaction of $233,350.00. Following the completion of the transaction, the director now owns 15,636 shares in the company, valued at approximately $3,648,660.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,425 shares of company stock worth $563,477. 0.36% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: Earnings Reports

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.